Drug News

Narcolepsy Drugs Market Soars to $5.95 Billion by 2030: Sodium Oxybate Takes Center Stage in Global Forecast

The Narcolepsy Drugs Market is on an upward trajectory, projected to reach a substantial value of US$5.95 billion by 2030, as revealed by the latest report from Research and Markets. Key drivers for this growth include the rising prevalence of narcolepsy, increased research and development investments, and the introduction of innovative therapeutic products.

Prevalence and Growth Factors

According to estimates by the National Institute of Neurological Disorders and Stroke (NINDS), between 135,000 to 200,000 people in the United States are affected by narcolepsy, a number expected to rise due to increasing stress levels.

Factors driving market growth include increasing stress, the introduction of novel therapeutic products, and growing investments in research and development.

Recent Developments

In July 2023, the U.S. Food and Drug Administration (FDA) conducted a comprehensive review of NLS Pharmaceutics’ research protocol for Mazindol ER, emphasizing a commitment to finding effective treatments for narcolepsy.

RareStone Group achieved a milestone in China with the approval of pitolisant (Wakix) by the Chinese National Medical Products Administration (NMPA) for narcolepsy treatment.

Steady Growth Projection

The Narcolepsy Drugs Market is anticipated to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.

Continuous drug development is crucial in managing narcolepsy symptoms, as there is no known cure for this lifelong condition.

Government Initiatives and Awareness

Governments in countries like India and South Africa actively support the production and use of narcolepsy drugs, promoting market growth.

Increased awareness of the benefits of narcolepsy drugs, coupled with a rise in disposable income, is expected to drive market development.

Segment Impact – Daytime Sleepiness Crucial

The narcolepsy drugs market is segmented into Daytime Extreme Sleepiness, Cataplexies, and Other Disease Types.

Daytime sleepiness significantly influences market dynamics, playing a pivotal role in shaping research, development, and the overall market landscape.

Sodium Oxybate Dominance

Sodium Oxybate leads therapeutic types, standing out for its widespread usage in treating narcolepsy symptoms.

FDA approval of Lumryz (sodium oxybate) in May 2023 for cataplexy and excessive daytime sleepiness further solidified its position.

End-User Segment – Diagnostics Centers Lead

Diagnostics Centers take the lead in the end-user segment, crucial in diagnosing and treating narcolepsy, underscoring their significance in addressing this neurological disorder.

Global Presence – U.S. at the Helm

The United States is a prominent player in the global narcolepsy drugs market, benefiting from advanced research and development, stringent regulatory requirements, and a high incidence of narcolepsy cases.

Key Players

Prominent companies in the Narcolepsy Drugs Market include Jazz Pharmaceuticals, Ligand Pharmaceuticals, Novartis AG, Takeda Pharmaceutical, Teva Pharmaceutical, Hikma Pharmaceuticals Plc, Harmony Biosciences Holdings, and Roche Holding AG.

The report provides a comprehensive overview of the narcolepsy drugs market, highlighting key trends, growth factors, and the role of major players in this evolving landscape.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker